NeuroLogica Gets FDA Nod for New Mobile CT Scanner
Enhancements for the BodyTom 64 Point-of-Care Mobile Computed Tomography (CT) Scanner include upgraded cross-sectional imaging capabilities and a Linux operating system.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the BodyTom® 64 Point-of-Care Mobile Computed Tomography Scanner, according to NeuroLogica, the manufacturer of the device and subsidiary of Samsung Electronics.
Incorporating clinician feedback in regard to the BodyTom Elite CT system, NeuroLogica doubled the capability of the BodyTom 64 system to generate upward of 64 cross-sectional images of a patient’s body and added a Linux operating system.
The device can reportedly be utilized in a variety of settings. For interventional radiologists, NeuroLogica said the BodyTom 64 provides multi-slice CT capabilities and facilitates easy rescans for stages of needle guidance. The BodyTom 64 device can provide neuroimaging guidance for extracranial procedures and is well-suited to trauma and emergency room settings with a unique combination of battery operation and internal lead shielding, added NeuroLogica.
“We’re thrilled to build off our expertise and elevate point-of-care imaging with our BodyTom64, which can transform any room in a hospital into an advanced imaging suite,” noted Jason Koshnitsky, senior director of Global Sales and Marketing at NeuroLogica.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
